Tag Archives: Oncology

Uncategorized

John Santilli quoted in Modern Medicine: FDA approves Cyramza in combination with paclitaxel for advanced gastric cancer after prior chemotherapy

Posted on by John Santilli

“Cyramza, approved earlier this year for stomach cancer, is a key product in Lilly’s oncology portfolio,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. “With the colorectal cancer market becoming increasingly crowded, Lilly will need to review the pricing strategy for Cyramza to make sure the drug remains competitive […]

Continue reading →
Market Intelligence

2015 Pharmaceutical Market Trend Vol. II

Posted on by John Santilli

Raising the Bar on performance So as to force companies to get lean, activist investors employ the use of shareholder arbitrage. There is increasing selection in licensing and partnering opportunities, and a reduced margin for error. Market-authorization for one-time results in periodic reevaluation throughout the life cycle of the product. There is relentlessness in the […]

Continue reading →
Market Intelligence

2015 Pharmaceutical Market Trend Vol. I

Posted on by aprilgregory

While the Pharmaceutical Industry has been experiencing many shifts and changes, it is still a 21st Century Growth Industry based on the stats, facts and trends put out by Pharm Exec.More growth expected… Basic science of genomics and biology are leading to a discovery of treatments which are advanced by using the body’s own immune […]

Continue reading →
Distribution

Genentech Distribution Decision

Posted on by John Santilli

This is an example of a pharmaceutical company helping another group of healthcare stakeholders, health plans, because of an issue with health systems increasing cost of care. Stakeholders in the healthcare market, while working to reduce the cost of care, are trying to determine the best path to profitability. An example is Genentech’s decision to […]

Continue reading →
Clinical Collaborations

Clinical trial collaborations – an idea whose time has come

Posted on by John Santilli

The cost and time commitment to develop new drugs has increased significantly over the last few decades. A variety of factors come into play, but on average, in terms of total expenditures, it has taken from $3 to $5 billion and up to 15 years to bring a new drug to market. Even after all […]

Continue reading →
Market Intelligence

Onco360 to distribute Gilead Sciences’ Zydelig

Posted on by AMI
28
Jul

Onco360 recently announced that it has been selected to be part of the limited network to distribute Gilead Sciences’ Zydelig (idelalisib) tablets. Onco360 is one of the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services companies. It will now be part of the highly limited Specialty Pharmacy network of Zydelig tablets, which has just […]

Continue reading →
Market Intelligence

ACA is Limiting Patient Access to Cancer Centers

Posted on by Dr. Randy

Some of America’s best cancer hospitals are off-limits to many of the people now signing up for coverage under the nation’s new health care program, according to a recent story in the Washington Post. An Associated Press survey found examples coast to coast. Seattle Cancer Care Alliance is excluded by five out of eight insurers […]

Continue reading →
Market Intelligence

CVS Caremark Acquires Navarro Discount Pharmacy

Posted on by AMI
15
Jul

CVS Caremark reached an agreement with Navarro, the largest Hispanic owned drugstore chain in the U.S., to acquire 33 stores and Navarro Health Services, a specialty pharmacy serving patients with complex or chronic diseases. CVS Caremark operates more than 7,600 stores, but said it will continue operating the acquired units under the Navarro banner. Navarro […]

Continue reading →